<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CEP</journal-id>
<journal-title-group>
<journal-title>Clinical and Experimental Pediatrics</journal-title><abbrev-journal-title>Clin Exp Pediatr</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2713-4148</issn>
<publisher>
<publisher-name>Korean Pediatric Society</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3345/cep.2024.00549</article-id>
<article-id pub-id-type="publisher-id">cep-2024-00549</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
<subj-group subj-group-type="heading">
<subject>Infection</subject>
</subj-group></subj-group></article-categories>
<title-group>
<article-title>Construction and validation of predictive models for intravenous immunoglobulin&#x02013;resistant Kawasaki disease using an interpretable machine learning approach</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Deng</surname><given-names>Linfan</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-cep-2024-00549"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2024-00549"><sup>2</sup></xref>
<xref ref-type="aff" rid="af3-cep-2024-00549"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhao</surname><given-names>Jian</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-cep-2024-00549"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2024-00549"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Ting</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af1-cep-2024-00549"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2024-00549"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Bin</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="af1-cep-2024-00549"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2024-00549"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jiang</surname><given-names>Jun</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="af4-cep-2024-00549"><sup>4</sup></xref>
<xref ref-type="aff" rid="af5-cep-2024-00549"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jia</surname><given-names>Peng</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="af6-cep-2024-00549"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Dong</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="corresp" rid="c1-cep-2024-00549"/>
<xref ref-type="aff" rid="af1-cep-2024-00549"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2024-00549"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0654-8232</contrib-id>
<name><surname>Li</surname><given-names>Gang</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="corresp" rid="c1-cep-2024-00549"/>
<xref ref-type="aff" rid="af1-cep-2024-00549"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2024-00549"><sup>2</sup></xref>
</contrib>
<aff id="af1-cep-2024-00549">
<label>1</label>Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, Luzhou, <country>China</country></aff>
<aff id="af2-cep-2024-00549">
<label>2</label>Sichuan Clinical Research Center for Birth Defects, Luzhou, <country>China</country></aff>
<aff id="af3-cep-2024-00549">
<label>3</label>Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, <country>China</country></aff>
<aff id="af4-cep-2024-00549">
<label>4</label>Department of General Surgery (Thyroid Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, <country>China</country></aff>
<aff id="af5-cep-2024-00549">
<label>5</label>Metabolic Vascular Diseases Key Laboratory of Sichuan Province, Luzhou, <country>China</country></aff>
<aff id="af6-cep-2024-00549">
<label>6</label>Department of Pediatrics, Zigong First People’s Hospital, Zigong, <country>China</country></aff>
</contrib-group>
<author-notes>
<corresp id="c1-cep-2024-00549">Corresponding Author: Gang Li. Department of Pediatrics, The Affiliated Hospital of Southwest Medical, University, No. 25 Taiping Street, Luzhou, Sichuan, China Email: <email>479719170@qq.com</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<month>8</month>
<year>2024</year></pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>7</month>
<year>2024</year></pub-date>
<volume>67</volume>
<issue>8</issue>
<fpage>405</fpage>
<lpage>414</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>03</month>
<year>2024</year></date>
<date date-type="rev-recd">
<day>27</day>
<month>04</month>
<year>2024</year></date>
<date date-type="accepted">
<day>10</day>
<month>05</month>
<year>2024</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x000a9; 2024 by The Korean Pediatric Society</copyright-statement>
<copyright-year>2024</copyright-year>
<license>
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions>
<abstract>
<sec><title>Background</title>
<p> Intravenous immunoglobulin (IVIG)-resistant Kawasaki disease is associated with coronary artery lesion development.</p></sec>
<sec><title>Purpose</title>
<p> This study aimed to explore the factors associated with IVIG-resistance and construct and validate an interpretable machine learning (ML) prediction model in clinical practice.</p></sec>
<sec><title>Methods</title>
<p> Between December 2014 and November 2022, 602 patients were screened and risk factors for IVIG-resistance investigated. Five ML models are used to establish an optimal prediction model. The SHapley Additive exPlanations (SHAP) method was used to interpret the ML model.</p></sec>
<sec><title>Results</title>
<p> Na<sup>&#x0002b;</sup>, hemoglobin (Hb), C-reactive protein (CRP), and globulin were independent risk factors for IVIG-resistance. A nonlinear relationship was identified between globulin level and IVIG-resistance. The XGBoost model exhibited excellent performance, with an area under the receiver operating characteristic curve of 0.821, accuracy of 0.748, sensitivity of 0.889, and specificity of 0.683 in the testing set. The XGBoost model was interpreted globally and locally using the SHAP method.</p></sec>
<sec><title>Conclusion</title>
<p> Na<sup>&#x0002b;</sup>, Hb, CRP, and globulin levels were independently associated with IVIG-resistance. Our findings demonstrate that ML models can reliably predict IVIG-resistance. Moreover, use of the SHAP method to interpret the established XGBoost model&#x00027;s findings would provide evidence of IVIG-resistance and guide the individualized treatment of Kawasaki disease.</p></sec>
</abstract>
<kwd-group>
<kwd>Kawasaki disease</kwd>
<kwd>Machine learning</kwd>
<kwd>Intravenous immunoglobulin resistance</kwd>
<kwd>SHapley Additive exPlanations</kwd>
</kwd-group>
</article-meta>
<notes>
<title>Key message</title>
<boxed-text>
<p><bold>Question:</bold> Is there a reliable model to predict intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD)?</p>
<p><bold>Finding:</bold> We constructed 5 machine learning models to predict IVIG-resistant KD. Extreme gradient boosting (XGBoost) model was superior to logistic, support vector machine, light gradient boosting machine and multiple layers perception models. The SHAP (SHapley Additive exPlanations) value interpreted the contribution of each feature in XGBoost model.</p>
<p><bold>Meaning:</bold> XGBoost model showed the excellent performance to predict IVIG-resistant KD with explainable and visualizable machine learning algorithm.</p>
</boxed-text>
</notes></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Kawasaki disease (KD) is an acute and immune-mediated vasculitis, principally influencing children under 5 years old. The coronary artery lesions (CALs) are the most common and detrimental complication, resulting in KD being emerged as the major cause of acquired heart disease in developed countries &#x0005b;<xref ref-type="bibr" rid="b1-cep-2024-00549">1</xref>&#x0005d;. The effective treatment with intravenous immunoglobulin (IVIG) and aspirin remarkably decreases the incidence of CALs from 25% to 4% &#x0005b;<xref ref-type="bibr" rid="b2-cep-2024-00549">2</xref>&#x0005d;, while there are approximately 10%&#x02013;20% of rate of IVIG-resistance after initial therapy. Remarkably, IVIG-resistance is widespread regarded as the risk factor for CALs. Therefore, it is crucial to construct a reliable model to predict IVIG-resistance and then conduct the suitable regimes as early as possible in order to decrease the occurrence of CALs.</p>
<p>In the past decade, numerous investigators worldwide have been exploring reliable predictive models or single indicators of-IVIG-resistance. Examples of such single predictors include peripheral blood cell parameters, C-reactive protein (CRP), procalcitonin, erythrocyte sedimentation rate (ESR), CRP/albumin (ALB) ratio &#x0005b;<xref ref-type="bibr" rid="b3-cep-2024-00549">3</xref>&#x0005d;, prognostic value of pretreatment prognostic nutritional index &#x0005b;<xref ref-type="bibr" rid="b4-cep-2024-00549">4</xref>&#x0005d;, serological indicators &#x0005b;<xref ref-type="bibr" rid="b5-cep-2024-00549">5</xref>,<xref ref-type="bibr" rid="b6-cep-2024-00549">6</xref>&#x0005d; and others. Additionally, various predictive models based on Japanese population, such as Egami &#x0005b;<xref ref-type="bibr" rid="b7-cep-2024-00549">7</xref>&#x0005d;, Kobayashi &#x0005b;<xref ref-type="bibr" rid="b8-cep-2024-00549">8</xref>&#x0005d;, and Sano &#x0005b;<xref ref-type="bibr" rid="b9-cep-2024-00549">9</xref>&#x0005d; have been extensively studied in other countries, demonstrating low sensitivity or specificity in other countries &#x0005b;<xref ref-type="bibr" rid="b10-cep-2024-00549">10</xref>-<xref ref-type="bibr" rid="b13-cep-2024-00549">13</xref>&#x0005d;. Obviously,the overall applicability of these models was limited in the general population.</p>
<p>Machine learning (ML) is an innovative field in medicine that holds promise for the future of biomedical research. ML has demonstrated its effectiveness in various diseases, including cancer &#x0005b;<xref ref-type="bibr" rid="b14-cep-2024-00549">14</xref>&#x0005d;, acute kidney injury &#x0005b;<xref ref-type="bibr" rid="b15-cep-2024-00549">15</xref>&#x0005d; and malnutrition &#x0005b;<xref ref-type="bibr" rid="b16-cep-2024-00549">16</xref>&#x0005d;. Some studies have shown that ML can accurately predict IVIG-resistance &#x0005b;<xref ref-type="bibr" rid="b17-cep-2024-00549">17</xref>,<xref ref-type="bibr" rid="b18-cep-2024-00549">18</xref>&#x0005d;. Extreme gradient boosting (XGBoost), logistic, support vector machine (SVM), light gradient boosting machine (LightGBM) and multiple layers perception (MLP) cloud enhance the optimization of the mathematical relationship between learning covariates and outcomes &#x0005b;<xref ref-type="bibr" rid="b19-cep-2024-00549">19</xref>&#x0005d;. Furthermore, ML-based models demonstrate superior performance in managing nonlinear data relationships, positioning them as an effective surrogate for predicting outcomes &#x0005b;<xref ref-type="bibr" rid="b20-cep-2024-00549">20</xref>&#x0005d;. However, the black box characteristic of ML algorithm may limit the trust of patients and clinicians, thereby impeding their widespread application in clinical settings. SHapley Additive exPlanations (SHAP) is a method utilized for interpreting individual predictions by determining the optimal Shapley value from game theory and TreeSHAP has been extensively utilized to facilitate the interpretation of ML algorithms, thereby overcoming the limitations of black box models. It can provide insights into the complex relationship between features and predictions, offering intuitive explanations, with significant advancements observed in the outcomes analysis of diseases &#x0005b;<xref ref-type="bibr" rid="b21-cep-2024-00549">21</xref>&#x0005d;. This can be particularly helpful for clinicians in understanding how the model accurately predicts outcomes and improving early interventions.</p>
<p>Therefore, the objectives of this study were threefold: first, to identify the associated risk factors of IVIG-resistance in the Mian Yang region; second, to develop and validate a high-performing ML model; and third, to interpret the ML model using SHAP.</p>
</sec>
<sec sec-type="methods">
<title>Methods</title>
<sec>
<title>1. Patients</title>
<p>The clinical data of eligible patients admitted to Mian yang Central Hospital between December 2014 and November 2022 were screened. The diagnostic criteria for KD followed the American Heart Association 2004 guidelines. IVIG-resistance was defined as the presence of persistent or recurrent fever lasting for at least 36 hours after the initial IVIG infusion. All patients received standard treatment, which included IVIG infusion (2g/kg) and oral aspirin (30&#x02013;50 mg/kg), within 10 days of disease onset. The exclusion criteria were as follows: (1) patients who did not receive IVIG therapy during hospitalization, (2) patients who received glucocorticoids or other immunosuppressive drugs during or before the initial IVIG therapy, (3) patients who were rehospitalized due to recurrence of KD, and (4) patients with a significant amount of missing clinical data (exceeding 20% of the total). During the acute fever period before IVIG treatment, various clinical data were collected, including white blood cell count, neutrophil count, lymphocyte (LYM) count, eosinophil (EOS) count, monocyte count, basophil count, platelet (PLT) count, hemoglobin (Hb) level, ESR, CRP level, gamma-glutamyl transpeptidase level, lactate dehydrogenase level, direct bilirubin (DBIL) level, total bilirubin (TBIL) level, globulin (GLO) level, ALB level, aspartate transaminase (AST)level, and alanine aminotransferase level. Throughout the entire study process, including clinical information collection, patients&#x00027; identity information was filtered to ensure patients&#x00027; privacy. This study was approved by the Ethics Committee on Human Subjects at Mianyang Central Hospital (No. KY2024062), in accordance with the 1975 Helsinki Declaration revised in 1996. Written informed consent was waived due to the retrospective nature and anonymity of the data.</p>
</sec>
<sec>
<title>2. Multiple ML algorithms</title>
<p>Each algorithm exhibits unique characteristics and capabilities within specific contexts. SVM is a versatile tool for linear/nonlinear classification tasks and is particularly useful for ML challenges with limited samples, albeit its performance is contingent upon parameter tuning and function selection &#x0005b;<xref ref-type="bibr" rid="b22-cep-2024-00549">22</xref>&#x0005d;. XGBoost, an ensemble learning algorithm, is adept at efficiently handling missing data to generate precise prediction models &#x0005b;<xref ref-type="bibr" rid="b23-cep-2024-00549">23</xref>&#x0005d;. The MLP is capable of learning nonlinear models and processing high-dimensional data, however, it necessitates rigorous standardization and preprocessing of the data, and is associated with a relatively lengthy training period &#x0005b;<xref ref-type="bibr" rid="b24-cep-2024-00549">24</xref>&#x0005d;. LightGBM demonstrates exceptional performance in processing extensive structured datasets at a rapid training pace, although it may be influenced by the number of features and sample size &#x0005b;<xref ref-type="bibr" rid="b25-cep-2024-00549">25</xref>,<xref ref-type="bibr" rid="b26-cep-2024-00549">26</xref>&#x0005d;.</p>
</sec>
<sec>
<title>3. Model interpretation</title>
<p>SHAP methodology was utilized to elucidate the optimal predictive model. Feature prioritization was achieved through the calculation of SHAP values, with features ranked based on the mean absolute value of their respective SHAP values. The integration of ML with SHAP has the potential to offer a clear rationale for the prediction model.</p>
</sec>
<sec>
<title>4. Statistical analysis</title>
<p>R ver. 4.2.3 (R Foundation for Statistical Computing, Vienna, Austria) and Python ver. 1.11.3 (Python Software Foundation) were chosen for statistical analysis. For ML models, Python (XGBoost, LightGBM, and scikit-learn) packages was used to construct models. Python ver. 0.43.0 was employed for SHAP analysis. Missing data (less than 20% of the total) was filled with random forest algorithms. Continuous data are expressed as median with interquartile range. Mann-Whitney <italic>U</italic> test and chi-square test were performed for continuous and categorical variables, respectively. The multivariable logistic regression analysis with backward stepwise selection was performed on the significant factors in univariate logistic analysis. A probability value of <italic>P</italic>&lt;0.05 was required for entry into the model and <italic>P</italic>&gt;0.05 for elimination. Relative risks were evaluated with odds ratios and 95% confidence intervals (CIs). In order to evaluate the dose association of independent risk factors with IVIG-resistance, a restricted cubic spline (RCS) was employed.</p>
<p>The whole data was randomly broken down into training and testing set based on the ratio of 8:2 in order to select the best prediction model. This random division was recured until the patient data were evenly distributed between the 2 groups. Five types of ML algorithm, including logistic, XGBoost, LightGBM, SVM, and MLP were developed to construct predictive model. Under the receiver operating characteristics curve, precision recall (PR) curves, area under PR (AP) curve and decision curve analysis (DCA) were employed to assess the predictive performance of each model in order to select the best-performing model. In addition, the accuracy, F1-score value, Kappa coefficient, sensitivity and specificity of each model also were used to further assess the models. Best hyperparameter and 10 cross-validation were used to avoid the risk of overfitting and heighten model accuracy. The selected optimal model was trained, verified, and tested using a 10-fold cross-validation technique. Additionally, SHAP analysis was conducted to determine the significance of individual features in the selected ML model. A 2-sided <italic>P</italic> value of less than 0.05 was considered statistically significant</p>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>1. Baseline characteristics</title>
<p><xref rid="t1-cep-2024-00549" ref-type="table">Table 1</xref> presents the demographic and laboratory parameters of the study participants. A total of 602 children with KD were recruited, out of which 68 (11.3%) experienced IVIG-resistance. The IVIG-resistant group exhibited higher levels of CRP, DBIL, TBIL, GLO, and AST, while showing lower counts of LYM, EOS, PLT, and lower levels of Hb, Na<sup>&#x0002b;</sup>, and ALB (all <italic>P</italic>&lt;0.05) when compared to the IVIG-responsive group.</p>
</sec>
<sec>
<title>2. Association between clinical indicators and IVIG-resistance</title>
<p>In univariate logistic analysis, lower LYM, EOS, Na<sup>&#x0002b;</sup>, Hb and ALB, as well as higher CRP, DBIL and GLO were associated with IVIG-resistance (<xref rid="t2-cep-2024-00549" ref-type="table">Table 2</xref>). However, multivariate logistic regression analysis showed that Na<sup>&#x0002b;</sup>, Hb, CRP, and GLO were independently correlated to IVIG-resistance (<xref rid="t2-cep-2024-00549" ref-type="table">Table 2</xref>).</p>
</sec>
<sec>
<title>3. Dose-response associations</title>
<p>The association between risk factors and IVIG-resistance based on RCS was analyzed, as shown in <xref rid="f1-cep-2024-00549" ref-type="fig">Fig. 1</xref>. Hb and Na<sup>&#x0002b;</sup> exhibited a linear and negative association with IVIG-resistance, with reference points at 105 g/Land 137 mmol/L, respectively (<xref rid="f1-cep-2024-00549" ref-type="fig">Fig. 1A</xref> and <xref rid="f1-cep-2024-00549" ref-type="fig">B</xref>). GLO showed a nonlinear and positive relationship with IVIG-resistance, displaying a V-shaped curve (all values of <italic>P</italic><sub>overall</sub> and <italic>P</italic><sub>nonlinear</sub> &lt;0.05) (<xref rid="f1-cep-2024-00549" ref-type="fig">Fig. 1C</xref>). The risk of IVIG-resistance increased rapidly when GLO levels exceeded approximately 22.5 g/L. CRP also showed a linear and positive association with IVIG-resistance (all values of <italic>P</italic><sub>overall</sub> &lt;0.05, and all values of <italic>P</italic><sub>nonlinear</sub> &gt;0.05) (<xref rid="f1-cep-2024-00549" ref-type="fig">Fig. 1D</xref>), with a risk threshold concentration of 75 mg/L.</p>
</sec>
<sec>
<title>4. Model constructing and evaluation</title>
<p>The baseline data of the training set and validation set was presented in <xref ref-type="supplementary-material" rid="SD1-cep-2024-00549">Supplementary Table 1</xref>. There was no significant difference between the 2 groups. The XGBoost, logistic, SVM, LightGBM, and MLP models based on 4 variables (Hb, CRP, Na<sup>&#x0002b;</sup>, and GLO) were built within the training sets. The results showed that the area under curve (AUC) of XGBoost was the highest in both the training set and validation set (<xref rid="f2-cep-2024-00549" ref-type="fig">Fig. 2A</xref> and <xref rid="f2-cep-2024-00549" ref-type="fig">B</xref>) (<xref ref-type="supplementary-material" rid="SD2-cep-2024-00549">Supplementary Tables 2</xref> and <xref ref-type="supplementary-material" rid="SD3-cep-2024-00549">3</xref>). Furthermore, XGBoost had the highest sensitivity, positive predictive value, negative predictive value, F1 score and Kappa in the training set and the validation set. Moreover, LightGBM has the highest accuracy and specificity, followed by XGBoost in the training set and the validation set, respectively (<xref ref-type="supplementary-material" rid="SD2-cep-2024-00549">Supplementary Tables 2</xref> and <xref ref-type="supplementary-material" rid="SD3-cep-2024-00549">3</xref>). Besides, DCA, calibration curves, and PR were also used to evaluate the performance efficiency of the 5 models. The DCA showed that logistic had better net benefits, followed by XGBoost (<xref rid="f3-cep-2024-00549" ref-type="fig">Fig. 3C</xref>). Calibration curves displayed the best accuracy of XGBoost models (<xref rid="f3-cep-2024-00549" ref-type="fig">Fig. 3D</xref>). XGBoost model indicated the optimal performance, as supported by the highest AP value in both the training and validation sets (<xref rid="f3-cep-2024-00549" ref-type="fig">Fig. 3E</xref> and <xref rid="f3-cep-2024-00549" ref-type="fig">F</xref>). Collectively, these analyses demonstrated that XGBoost was considered to be the optimal model.</p>
</sec>
<sec>
<title>5. The optimal model building and evaluation</title>
<p>XGBoost and 10-fold cross-validation were performed on the training set. The average AUC for the training set, verification set, and testing set were 0.935 (95% CI, 0.904&#x02013;0.966), 0.774 (95% CI, 0.565&#x02013;0.964), and 0.821 (95% CI, 0.698&#x02013;0.944), respectively, as shown in <xref rid="f2-cep-2024-00549" ref-type="fig">Fig. 2A</xref>&#x02013;<xref rid="f2-cep-2024-00549" ref-type="fig">C</xref>. The AUC index of the validation set did not exceed that of the test set, or the exceedance ratio was less than 10%, indicating successful model fitting. The learning curve demonstrated a strong fit and high stability of the training set and the verification set (<xref rid="f2-cep-2024-00549" ref-type="fig">Fig. 2D</xref>). These results indicate that the XGBoost model is suitable for the classification modeling task with the current data.</p>
</sec>
<sec>
<title>6. XGBoost model interpretation with SHAP method</title>
<p>The SHAP method was utilized to explain how the selected variables predicted the likelihood of IVIG-resistance in the model. In <xref rid="f4-cep-2024-00549" ref-type="fig">Fig. 4A</xref>, the 4 most important features were displayed in the current model. Each feature had a significant line, and different colored dots represented the attribution of outcomes for all patients. The red and blue points indicated high and low risk values, respectively. The risk of IVIG-resistance was found to increase with decreased levels of Hb and Na<sup>&#x0002b;</sup>, and increased levels of GLO and CRP. <xref rid="f4-cep-2024-00549" ref-type="fig">Fig. 4B</xref> demonstrated that the 4 predictors were ranked based on their average absolute SHAP value. Furthermore, 2 typical cases were used to highlight the interpretability of the XGBoost model. The patient with IVIG-resistance had a high SHAP value (0.69) (<xref rid="f4-cep-2024-00549" ref-type="fig">Fig. 4C</xref>), while another patient without IVIG-resistance showed a low SHAP value (0.02) (<xref rid="f4-cep-2024-00549" ref-type="fig">Fig. 4D</xref>).</p>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In this retrospective study, we investigated the dependent risk factors of IVIG-resistance. We developed and validated 5 ML algorithms to predict IVIG-resistance. Na<sup>&#x0002b;</sup>, Hb, CRP and GLO were identified as independent risk factors for IVIG-resistance. Additionally, we observed a nonlinear relationship between GLO and IVIG-resistance. Among these models, the XGBoost model demonstrated superior performance compared to logistic, SVM, MLP, and LightGBM.</p>
<p>The existing prediction models for IVIG-resistance have not performed satisfactorily in other regions. In the past, logistic regression mode was commonly used to establish prediction models for IVIG-resistance, but they were not suitable for dealing with high-latitude, large-volume data. In contrast, ML algorithms could exhibit excellent performance than traditional logistic model &#x0005b;<xref ref-type="bibr" rid="b27-cep-2024-00549">27</xref>,<xref ref-type="bibr" rid="b28-cep-2024-00549">28</xref>&#x0005d;. In the present study, XGBoost model exhibited the best performance than other models (logistic, SVM, MLP, and LightGBM) in the internal validation set, as assessing the PR curves, calibration curves, AUC and DCA. Previous studies indicated that LightGBM model was superior to other models (Logistic regression, SVM, XGBoost) to predict IVIG-resistance &#x0005b;<xref ref-type="bibr" rid="b17-cep-2024-00549">17</xref>,<xref ref-type="bibr" rid="b29-cep-2024-00549">29</xref>&#x0005d;, implying the excellent predictive performance of ML algorithms. Although the optimal ML model was different between our study and previous studies &#x0005b;<xref ref-type="bibr" rid="b17-cep-2024-00549">17</xref>,<xref ref-type="bibr" rid="b29-cep-2024-00549">29</xref>&#x0005d;, it may be duo to different selection of feature variables.In this study, in order to control confounding factors, we identified risk factors based multivariate logistic regression, and then construct IVIG-resistant ML models with these risk factors. Additionally, Wang et al. &#x0005b;<xref ref-type="bibr" rid="b30-cep-2024-00549">30</xref>&#x0005d; found that XGBoost also displayed satisfactory performance to predict 3-year all-cause mortality in patients with heart failure compared with SVM, MLP, logistic regression, k-nearest neighbors, and naive Bayesian models. The optimal model we developed could assist pediatricians in identifying high-risk patients. If the model discriminated patients with high probability of IVIG-resistance, appropriate regiments can be implemented during the initial treatment to decrease the risk of CALs. However, further investigations should be taken to confirm the performance of this model.</p>
<p>The utilization of ML is often impeded by the inexplicable and unobservable attributes, leading to doubts regarding the applicability of such algorithms in forecasting disease occurrences within clinical environments. As such, we estimated SHAP value of XGBoost model to interpret and visualize the prediction results, whereby establishing a score system to predict IVIG-resistance. Likewise, the application of it was found in survival prognosis of cancer &#x0005b;<xref ref-type="bibr" rid="b21-cep-2024-00549">21</xref>&#x0005d;, which served as the theoretical framework and practical foundation for related research endeavors. In present study, Hb was the most important index in IVIG-resistance, followed by GLO, CRP and Na<sup>&#x0002b;</sup>. All of them were independently associated with IVIG-resistance. Actually, A reduction in Hb levels may result in insufficient oxygen delivery, particularly in compromised blood vessels, thereby exacerbating vascular damage and inflammatory reactions, consequently heightening the susceptibility to cardiovascular events. Furthermore, Hb serves as a crucial diagnostic marker for anemia, the presence of which was associated with KD &#x0005b;<xref ref-type="bibr" rid="b31-cep-2024-00549">31</xref>&#x0005d; and decreased Hb was positively associated with IVIG-resistance &#x0005b;<xref ref-type="bibr" rid="b32-cep-2024-00549">32</xref>&#x0005d;. Our results seems to be in line with previous study indicating that low Na<sup>&#x0002b;</sup> levels &#x0005b;<xref ref-type="bibr" rid="b33-cep-2024-00549">33</xref>&#x0005d; and high CRP &#x0005b;<xref ref-type="bibr" rid="b7-cep-2024-00549">7</xref>,<xref ref-type="bibr" rid="b33-cep-2024-00549">33</xref>&#x0005d;. were associated with IVIG-resistance. In addition, there was a dose-dependent relationship between GLO and IVIG-resistance, whereby an increased risk of IVIG-resistance was observed when GLO exceeded 22.5 g/L. In fact, numerous studies have showed that elevated GLO levels are associated with infection &#x0005b;<xref ref-type="bibr" rid="b34-cep-2024-00549">34</xref>&#x0005d; and mortality &#x0005b;<xref ref-type="bibr" rid="b35-cep-2024-00549">35</xref>,<xref ref-type="bibr" rid="b36-cep-2024-00549">36</xref>&#x0005d;, thereby supporting our findings, to some extent. The comprehensive data outlined in the results and elucidation of risk factors offer doctors a deeper understanding, enabling them to make well-informed decisions rather than relying solely on algorithmic outputs. Moreover, individualized explanations can aid in the comprehension of the rationale behind the model&#x00027;s recommendations for critical decisions. However, further research is need to evaluate the practicality of the SHAP method.</p>
<p>However, there are several limitations that should not be ignored in this study. Firstly, the sample size in our study was relatively small. Secondly, selection bias was inevitable due to the retrospective nature of the study. Thirdly, The ML model we constructed was limited to one institution, which may restrict its practicality and needs validation in external datasets. Finally, although our XGBoost model can be interpreted by SHAP, it would be beneficial to explore other popular interpretable models for pediatricians to consider.</p>
<p>In conclusion, our results indicated that Na<sup>&#x0002b;</sup>, Hb, CRP, and GLO were the independent risk factors for IVIG-resistance. We constructed an IVIG-resistance prediction model using a ML algorithm, with the XGBoost model demonstrating the best performance. The interpretability method was employed to explain the XGBoost model, which has significant clinical value and can assist pediatricians in effectively managing KD patients by maximizing the identification of high-risk patients.</p>
</sec>
</body>
<back>
<sec sec-type="supplementary-material"><title>Supplementary materials</title>
<p>Supplementary Tables 1–3 can be found via <ext-link xlink:href="https://doi.org/10.3345/cep.2024.00549" ext-link-type="uri">https://doi.org/10.3345/cep.2024.00549</ext-link>.</p>
<supplementary-material content-type="loca-data" id="SD1-cep-2024-00549">
<p><bold>Supplementary Table 1.</bold> Baseline characteristics in training cohort and validation cohort</p>
<media mimetype="application" mime-subtype="pdf" xlink:href="cep-2024-00549-Supplementary-Table-1.pdf"/></supplementary-material>
<supplementary-material content-type="loca-data" id="SD2-cep-2024-00549">
<p><bold>Supplementary Table 2.</bold> Performance of each model for prediction (training set)</p>
<media mimetype="application" mime-subtype="pdf" xlink:href="cep-2024-00549-Supplementary-Table-2.pdf"/></supplementary-material>
<supplementary-material content-type="loca-data" id="SD3-cep-2024-00549">
<p><bold>Supplementary Table 3.</bold> Performance of each model for prediction (training set)</p>
<media mimetype="application" mime-subtype="pdf" xlink:href="cep-2024-00549-Supplementary-Table-3.pdf"/></supplementary-material>
</sec>
<fn-group>
<fn fn-type="conflict"><p><bold>Conflicts of interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn>
<fn fn-type="financial-disclosure"><p><bold>Funding</bold></p><p>This work was supported by Sichuan Science and Technology Program (No. 2022YFS0627) and Luzhou Municipal People's Government-Southwest Medical University Science and Technology strategic cooperation (No. 2023LZXNYDJ042).</p></fn>
<fn fn-type="participating-researchers"><p><bold>Author contribution</bold></p><p>Conceptualization: GL, DL; Formal analysis: JZ, PJ, TW; Investigation: JZ, PJ, TW; Methodology; JZ, PJ, TW; Project administration: JJ, BL; Writing–original draft: LD; Writing–review &amp; editing: GL.</p></fn>
</fn-group>
<ack><p>This work was supported by Extreme Smart Analysis platform (<ext-link xlink:href="https://www.xsmartanalysis.com/" ext-link-type="uri">https://www.xsmartanalysis.com/</ext-link>).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-cep-2024-00549">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>S</given-names></name>
<name><surname>Vignesh</surname><given-names>P</given-names></name>
<name><surname>Burgner</surname><given-names>D</given-names></name>
</person-group>
<article-title>The epidemiology of Kawasaki disease: a global update</article-title>
<source>Arch Dis Child</source>
<year>2015</year>
<volume>100</volume>
<fpage>1084</fpage>
<lpage>8</lpage>
</element-citation></ref>
<ref id="b2-cep-2024-00549">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>McCrindle</surname><given-names>BW</given-names></name>
<name><surname>Rowley</surname><given-names>AH</given-names></name>
<name><surname>Newburger</surname><given-names>JW</given-names></name>
<name><surname>Burns</surname><given-names>JC</given-names></name>
<name><surname>Bolger</surname><given-names>AF</given-names></name>
<name><surname>Gewitz</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association</article-title>
<source>Circulation</source>
<year>2017</year>
<volume>135</volume>
<fpage>e927</fpage>
<lpage>99</lpage>
</element-citation></ref>
<ref id="b3-cep-2024-00549">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Wang</surname><given-names>T</given-names></name>
<name><surname>Gou</surname><given-names>Y</given-names></name>
<name><surname>Zeng</surname><given-names>R</given-names></name>
<name><surname>Liu</surname><given-names>D</given-names></name>
<name><surname>Duan</surname><given-names>Y</given-names></name>
<etal/>
</person-group>
<article-title>Value of C-reactive protein/albumin ratio in predicting intravenous immunoglobulin-resistant Kawasaki disease- a data from multiinstitutional study in China</article-title>
<source>Int Immunopharmacol</source>
<year>2020</year>
<volume>89</volume>
<issue>Pt A</issue>
<fpage>107037</fpage>
</element-citation></ref>
<ref id="b4-cep-2024-00549">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Xu</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>P</given-names></name>
<name><surname>Zeng</surname><given-names>R</given-names></name>
<name><surname>Liu</surname><given-names>B</given-names></name>
</person-group>
<article-title>Prognostic value of pretreatment prognostic nutritional index in intravenous immunoglobulin-resistant Kawasaki disease</article-title>
<source>Heart Vessels</source>
<year>2021</year>
<volume>36</volume>
<fpage>1366</fpage>
<lpage>73</lpage>
</element-citation></ref>
<ref id="b5-cep-2024-00549">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Wang</surname><given-names>T</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>P</given-names></name>
<name><surname>Jia</surname><given-names>P</given-names></name>
<name><surname>Zhao</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<article-title>Increased concentrations of growth differentiation factor-15 in children with Kawasaki disease</article-title>
<source>Clin Chim Acta</source>
<year>2020</year>
<volume>507</volume>
<fpage>264</fpage>
<lpage>70</lpage>
</element-citation></ref>
<ref id="b6-cep-2024-00549">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Duan</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Luo</surname><given-names>D</given-names></name>
<name><surname>Jiang</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>B</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
</person-group>
<article-title>Serum IL-41 might be a biomarker for IVIG resistance and coronary artery lesions in Kawasaki disease</article-title>
<source>Int Immunopharmacol</source>
<year>2023</year>
<volume>122</volume>
<fpage>110600</fpage>
</element-citation></ref>
<ref id="b7-cep-2024-00549">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Egami</surname><given-names>K</given-names></name>
<name><surname>Muta</surname><given-names>H</given-names></name>
<name><surname>Ishii</surname><given-names>M</given-names></name>
<name><surname>Suda</surname><given-names>K</given-names></name>
<name><surname>Sugahara</surname><given-names>Y</given-names></name>
<name><surname>Iemura</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease</article-title>
<source>J Pediatr</source>
<year>2006</year>
<volume>149</volume>
<fpage>237</fpage>
<lpage>40</lpage>
</element-citation></ref>
<ref id="b8-cep-2024-00549">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>T</given-names></name>
<name><surname>Inoue</surname><given-names>Y</given-names></name>
<name><surname>Takeuchi</surname><given-names>K</given-names></name>
<name><surname>Okada</surname><given-names>Y</given-names></name>
<name><surname>Tamura</surname><given-names>K</given-names></name>
<name><surname>Tomomasa</surname><given-names>T</given-names></name>
<etal/>
</person-group>
<article-title>Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease</article-title>
<source>Circulation</source>
<year>2006</year>
<volume>113</volume>
<fpage>2606</fpage>
<lpage>12</lpage>
</element-citation></ref>
<ref id="b9-cep-2024-00549">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sano</surname><given-names>T</given-names></name>
<name><surname>Kurotobi</surname><given-names>S</given-names></name>
<name><surname>Matsuzaki</surname><given-names>K</given-names></name>
<name><surname>Yamamoto</surname><given-names>T</given-names></name>
<name><surname>Maki</surname><given-names>I</given-names></name>
<name><surname>Miki</surname><given-names>K</given-names></name>
<etal/>
</person-group>
<article-title>Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment</article-title>
<source>Eur J Pediatr</source>
<year>2007</year>
<volume>166</volume>
<fpage>131</fpage>
<lpage>7</lpage>
</element-citation></ref>
<ref id="b10-cep-2024-00549">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sleeper</surname><given-names>LA</given-names></name>
<name><surname>Minich</surname><given-names>LL</given-names></name>
<name><surname>McCrindle</surname><given-names>BM</given-names></name>
<name><surname>Li</surname><given-names>JS</given-names></name>
<name><surname>Mason</surname><given-names>W</given-names></name>
<name><surname>Colan</surname><given-names>SD</given-names></name>
<etal/>
</person-group>
<article-title>Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance</article-title>
<source>J Pediatr</source>
<year>2011</year>
<volume>158</volume>
<fpage>831</fpage>
<lpage>5.e3</lpage>
</element-citation></ref>
<ref id="b11-cep-2024-00549">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tremoulet</surname><given-names>AH</given-names></name>
<name><surname>Best</surname><given-names>BM</given-names></name>
<name><surname>Song</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>S</given-names></name>
<name><surname>Corinaldesi</surname><given-names>E</given-names></name>
<name><surname>Eichenfield</surname><given-names>JR</given-names></name>
<etal/>
</person-group>
<article-title>Resistance to intravenous immunoglobulin in children with Kawasaki disease</article-title>
<source>J Pediatr</source>
<year>2008</year>
<volume>153</volume>
<fpage>117</fpage>
<lpage>21</lpage>
</element-citation></ref>
<ref id="b12-cep-2024-00549">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>S&#x000e1;nchez-Manubens</surname><given-names>J</given-names></name>
<name><surname>Ant&#x000f3;n</surname><given-names>J</given-names></name>
<name><surname>Bou</surname><given-names>R</given-names></name>
<name><surname>Iglesias</surname><given-names>E</given-names></name>
<name><surname>Calzada-Hernandez</surname><given-names>J</given-names></name>
<name><surname>Borlan</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population</article-title>
<source>Rheumatol Int</source>
<year>2016</year>
<volume>36</volume>
<fpage>905</fpage>
<lpage>10</lpage>
</element-citation></ref>
<ref id="b13-cep-2024-00549">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>R</given-names></name>
<name><surname>Yao</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
</person-group>
<article-title>Efficacy of four scoring systems in predicting intravenous immunoglobulin resistance in children with Kawasaki disease in a children&#x00027;s hospital in Beijing, North China</article-title>
<source>J Pediatr</source>
<year>2017</year>
<volume>184</volume>
<fpage>120</fpage>
<lpage>4</lpage>
</element-citation></ref>
<ref id="b14-cep-2024-00549">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ek&#x0015f;i</surname><given-names>M</given-names></name>
<name><surname>Evren</surname><given-names>&#x00130;</given-names></name>
<name><surname>Akka</surname><given-names>F</given-names></name>
<name><surname>Ar&#x00131;kan</surname><given-names>Y</given-names></name>
<name><surname>&#x000d6;zdemir</surname><given-names>O</given-names></name>
<name><surname>&#x000d6;zl&#x000fc;</surname><given-names>DN</given-names></name>
<etal/>
</person-group>
<article-title>Machine learning algorithms can more efficiently predict biochemical recurrence after robot-assisted radical prostatectomy</article-title>
<source>Prostate</source>
<year>2021</year>
<volume>81</volume>
<fpage>913</fpage>
<lpage>20</lpage>
</element-citation></ref>
<ref id="b15-cep-2024-00549">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fan</surname><given-names>Z</given-names></name>
<name><surname>Jiang</surname><given-names>J</given-names></name>
<name><surname>Xiao</surname><given-names>C</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Xia</surname><given-names>Q</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<article-title>Construction and validation of prognostic models in critically Ill patients with sepsis-associated acute kidney injury: interpretable machine learning approach</article-title>
<source>J Transl Med</source>
<year>2023</year>
<volume>21</volume>
<fpage>406</fpage>
</element-citation></ref>
<ref id="b16-cep-2024-00549">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Talukder</surname><given-names>A</given-names></name>
<name><surname>Ahammed</surname><given-names>B</given-names></name>
</person-group>
<article-title>Machine learning algorithms for predicting malnutrition among under-five children in Bangladesh</article-title>
<source>Nutrition</source>
<year>2020</year>
<volume>78</volume>
<fpage>110861</fpage>
</element-citation></ref>
<ref id="b17-cep-2024-00549">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Huang</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Ma</surname><given-names>Y</given-names></name>
<etal/>
</person-group>
<article-title>A machine learning model to predict intravenous immunoglobulin-resistant Kawasaki disease patients: a retrospective study based on the Chongqing population</article-title>
<source>Front Pediatr</source>
<year>2021</year>
<volume>9</volume>
<fpage>756095</fpage>
</element-citation></ref>
<ref id="b18-cep-2024-00549">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kuniyoshi</surname><given-names>Y</given-names></name>
<name><surname>Tokutake</surname><given-names>H</given-names></name>
<name><surname>Takahashi</surname><given-names>N</given-names></name>
<name><surname>Kamura</surname><given-names>A</given-names></name>
<name><surname>Yasuda</surname><given-names>S</given-names></name>
<name><surname>Tashiro</surname><given-names>M</given-names></name>
</person-group>
<article-title>Comparison of machine learning models for prediction of initial intravenous immunoglobulin resistance in children with Kawasaki disease</article-title>
<source>Front Pediatr</source>
<year>2020</year>
<volume>8</volume>
<fpage>570834</fpage>
</element-citation></ref>
<ref id="b19-cep-2024-00549">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>W</given-names></name>
<name><surname>Zhao</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>S</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Jiang</surname><given-names>K</given-names></name>
<name><surname>Ji</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<article-title>Explainable and visualizable machine learning models to predict biochemical recurrence of prostate cancer</article-title>
<source>Clin Transl Oncol</source>
<year>2024</year>
<month>Apr</month>
<day>11</day>
<comment>doi: 10.1007/s12094-024-03480-x.[Epub]</comment>
</element-citation></ref>
<ref id="b20-cep-2024-00549">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zuo</surname><given-names>D</given-names></name>
<name><surname>Yang</surname><given-names>L</given-names></name>
<name><surname>Jin</surname><given-names>Y</given-names></name>
<name><surname>Qi</surname><given-names>H</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Ren</surname><given-names>L</given-names></name>
</person-group>
<article-title>Machine learning-based models for the prediction of breast cancer recurrence risk</article-title>
<source>BMC Med Inform Decis Mak</source>
<year>2023</year>
<volume>23</volume>
<fpage>276</fpage>
</element-citation></ref>
<ref id="b21-cep-2024-00549">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Moncada-Torres</surname><given-names>A</given-names></name>
<name><surname>van Maaren</surname><given-names>MC</given-names></name>
<name><surname>Hendriks</surname><given-names>MP</given-names></name>
<name><surname>Siesling</surname><given-names>S</given-names></name>
<name><surname>Geleijnse</surname><given-names>G</given-names></name>
</person-group>
<article-title>Explainable machine learning can outperform Cox regression predictions and provide insights in breast cancer survival</article-title>
<source>Sci Rep</source>
<year>2021</year>
<volume>11</volume>
<fpage>6968</fpage>
</element-citation></ref>
<ref id="b22-cep-2024-00549">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>S</given-names></name>
</person-group>
<article-title>Sparse SVM for sufficient data reduction</article-title>
<source>IEEE Trans Pattern Anal Mach Intell</source>
<year>2022</year>
<volume>44</volume>
<fpage>5560</fpage>
<lpage>71</lpage>
</element-citation></ref>
<ref id="b23-cep-2024-00549">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hou</surname><given-names>N</given-names></name>
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>He</surname><given-names>L</given-names></name>
<name><surname>Xie</surname><given-names>B</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>R</given-names></name>
<etal/>
</person-group>
<article-title>Predicting 30-days mortality for MIMIC-III patients with sepsis-3: a machine learning approach using XGboost</article-title>
<source>J Transl Med</source>
<year>2020</year>
<volume>18</volume>
<fpage>462</fpage>
</element-citation></ref>
<ref id="b24-cep-2024-00549">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lorencin</surname><given-names>I</given-names></name>
<name><surname>An&#x00111;eli&#x00107;</surname><given-names>N</given-names></name>
<name><surname>&#x00160;panjol</surname><given-names>J</given-names></name>
<name><surname>Car</surname><given-names>Z</given-names></name>
</person-group>
<article-title>Using multi-layer perceptron with La placian edge detector for bladder cancer diagnosis</article-title>
<source>Artif Intell Med</source>
<year>2020</year>
<volume>102</volume>
<fpage>101746</fpage>
</element-citation></ref>
<ref id="b25-cep-2024-00549">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yan</surname><given-names>J</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Cheng</surname><given-names>Q</given-names></name>
<name><surname>Jiang</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>Q</given-names></name>
<name><surname>Xiao</surname><given-names>Y</given-names></name>
<etal/>
</person-group>
<article-title>LightGBM: accelerated genomically designed crop breeding through ensemble learning</article-title>
<source>Genome Biol</source>
<year>2021</year>
<volume>22</volume>
<fpage>271</fpage>
</element-citation></ref>
<ref id="b26-cep-2024-00549">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sadozai</surname><given-names>H</given-names></name>
<name><surname>Acharjee</surname><given-names>A</given-names></name>
<name><surname>Eppenberger-Castori</surname><given-names>S</given-names></name>
<name><surname>Gloor</surname><given-names>B</given-names></name>
<name><surname>Gruber</surname><given-names>T</given-names></name>
<name><surname>Schenk</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Distinct stromal and immune features collectively contribute to long-term survival in pancreatic cancer</article-title>
<source>Front Immunol</source>
<year>2021</year>
<volume>12</volume>
<fpage>643529</fpage>
</element-citation></ref>
<ref id="b27-cep-2024-00549">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>X</given-names></name>
<name><surname>Sun</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>X</given-names></name>
<name><surname>Steyerberg</surname><given-names>EW</given-names></name>
<name><surname>Helmrich</surname><given-names>IRAR</given-names></name>
<name><surname>Lecky</surname><given-names>F</given-names></name>
<etal/>
</person-group>
<article-title>Mortality prediction in severe traumatic brain injury using traditional and machine learning algorithms</article-title>
<source>J Neurotrauma</source>
<year>2023</year>
<volume>40</volume>
<fpage>1366</fpage>
<lpage>75</lpage>
</element-citation></ref>
<ref id="b28-cep-2024-00549">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>R</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>He</surname><given-names>M</given-names></name>
<name><surname>Xu</surname><given-names>J</given-names></name>
</person-group>
<article-title>XGBoost machine learning algorism performed better than regression models in predicting mortality of moderate-to-severe traumatic brain injury</article-title>
<source>World Neurosurg</source>
<year>2022</year>
<volume>163</volume>
<fpage>e617</fpage>
<lpage>22</lpage>
</element-citation></ref>
<ref id="b29-cep-2024-00549">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sunaga</surname><given-names>Y</given-names></name>
<name><surname>Watanabe</surname><given-names>A</given-names></name>
<name><surname>Katsumata</surname><given-names>N</given-names></name>
<name><surname>Toda</surname><given-names>T</given-names></name>
<name><surname>Yoshizawa</surname><given-names>M</given-names></name>
<name><surname>Kono</surname><given-names>Y</given-names></name>
<etal/>
</person-group>
<article-title>A simple scoring model based on machine learning predicts intravenous immunoglobulin resistance in Kawasaki disease</article-title>
<source>Clin Rheumatol</source>
<year>2023</year>
<volume>42</volume>
<fpage>1351</fpage>
<lpage>61</lpage>
</element-citation></ref>
<ref id="b30-cep-2024-00549">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>K</given-names></name>
<name><surname>Tian</surname><given-names>J</given-names></name>
<name><surname>Zheng</surname><given-names>C</given-names></name>
<name><surname>Yang</surname><given-names>H</given-names></name>
<name><surname>Ren</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<etal/>
</person-group>
<article-title>Interpretable prediction of 3-year all-cause mortality in patients with heart failure caused by coronary heart disease based on machine learning and SHAP</article-title>
<source>Comput Biol Med</source>
<year>2021</year>
<volume>137</volume>
<fpage>104813</fpage>
</element-citation></ref>
<ref id="b31-cep-2024-00549">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>YH</given-names></name>
<name><surname>Kuo</surname><given-names>HC</given-names></name>
</person-group>
<article-title>Anemia in Kawasaki disease: hepcidin as a potential biomarker</article-title>
<source>Int J Mol Sci</source>
<year>2017</year>
<volume>18</volume>
<fpage>820</fpage>
</element-citation></ref>
<ref id="b32-cep-2024-00549">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Atsumi</surname><given-names>Y</given-names></name>
<name><surname>Sakakibara</surname><given-names>H</given-names></name>
<name><surname>Morikawa</surname><given-names>Y</given-names></name>
<name><surname>Miyata</surname><given-names>K</given-names></name>
<name><surname>Yamagishi</surname><given-names>H</given-names></name>
<name><surname>Misawa</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Decreased hemoglobin after initial treatment is associated with treatment resistance in Kawasaki disease in Kobayashi risk stratification</article-title>
<source>World J Pediatr</source>
<year>2020</year>
<volume>16</volume>
<fpage>623</fpage>
<lpage>8</lpage>
</element-citation></ref>
<ref id="b33-cep-2024-00549">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S</given-names></name>
<name><surname>Song</surname><given-names>R</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>C</given-names></name>
</person-group>
<article-title>Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing</article-title>
<source>Arch Dis Child</source>
<year>2019</year>
<volume>104</volume>
<fpage>262</fpage>
<lpage>7</lpage>
</element-citation></ref>
<ref id="b34-cep-2024-00549">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shang</surname><given-names>G</given-names></name>
<name><surname>Fei</surname><given-names>Z</given-names></name>
<name><surname>Xu</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Xiang</surname><given-names>S</given-names></name>
</person-group>
<article-title>Globulin and albumin to globulin ratio precisely diagnose periprosthetic joint infection and determine the timing of second-stage reimplantation</article-title>
<source>J Orthop Surg Res</source>
<year>2022</year>
<volume>17</volume>
<fpage>12</fpage>
</element-citation></ref>
<ref id="b35-cep-2024-00549">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lai</surname><given-names>KJ</given-names></name>
<name><surname>Hsieh</surname><given-names>YP</given-names></name>
<name><surname>Chiu</surname><given-names>PF</given-names></name>
<name><surname>Lin</surname><given-names>PR</given-names></name>
</person-group>
<article-title>Association of albumin and globulin with mortality risk in incident peritoneal dialysis patients</article-title>
<source>Nutrients</source>
<year>2022</year>
<volume>14</volume>
<fpage>2850</fpage>
</element-citation></ref>
<ref id="b36-cep-2024-00549">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pai</surname><given-names>AY</given-names></name>
<name><surname>Sy</surname><given-names>J</given-names></name>
<name><surname>Kim</surname><given-names>J</given-names></name>
<name><surname>Kleine</surname><given-names>CE</given-names></name>
<name><surname>Edward</surname><given-names>J</given-names></name>
<name><surname>Hsiung</surname><given-names>JT</given-names></name>
<etal/>
</person-group>
<article-title>Association of serum globulin with all-cause mortality in incident hemodialysis patients</article-title>
<source>Nephrol Dial Transplant</source>
<year>2022</year>
<volume>37</volume>
<fpage>1993</fpage>
<lpage>2003</lpage>
</element-citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures and Tables</title>
<fig id="f1-cep-2024-00549" position="float">
<label>Fig. 1.</label><caption><p>Dose-dependent associations between risk factors and intravenous immuno globulin resistance using restricted cubic spline. Hb, hemoglobin; GLO, globulin; CRP, C-reactive protein; CI, confidence interval. (A) Hb, (B) Na<sup>+</sup>, (C) GLO, (D) CRP.</p></caption>
<graphic xlink:href="cep-2024-00549f1.tif"/></fig>
<fig id="f2-cep-2024-00549" position="float">
<label>Fig. 2.</label><caption><p>XGBoost model training, validation, and testing. (A) ROC and AUC of the training set. (B) ROC and AUC of the validation set. (C) ROC and AUC of the testing set. (D) Learning curve. ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval.</p></caption>
<graphic xlink:href="cep-2024-00549f2.tif"/></fig>
<fig id="f3-cep-2024-00549" position="float">
<label>Fig. 3.</label><caption><p>Comparison of 5 ML models. (A) Training set ROC and AUC. (B) Validation set ROC and AUC. (C) DCA of the 5 ML models. (D) Calibration curve of the validation set. (E) Training set PR curve and AP. (F) Validation set PR curve and AP. ML, machine learning; ROC, receiver operating characteristic; AUC, area under the curve; DCA, decision curve analysis; PR, precision recall; AP, area under the precision recall curve CI, confidence interval.</p></caption>
<graphic xlink:href="cep-2024-00549f3.tif"/></fig>
<fig id="f4-cep-2024-00549" position="float">
<label>Fig. 4.</label><caption><p>SHAP method used to interpret the model. (A) The SHAP values of the 4 important features. The higher the SHAP value of a feature, the higher the risk of IVIG-resistance. (B) Importance matrix plot of the 4 features. The SHAP value of each feature is shown in descending order. (C) Individual efforts by patients with IVIG-resistance. (D) Individual efforts by patients without IVIG-resistance. SHAP, SHapley Additive exPlanations; IVIG, intravenous immunoglobulin; Hb, hemoglobin; GLO, globulin; CRP, C-reactive protein.</p></caption>
<graphic xlink:href="cep-2024-00549f4.tif"/></fig>

<table-wrap id="t1-cep-2024-00549" position="float">
<label>Table 1.</label>
<caption><p>Clinical baseline information for all patients</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">Variable</th>
<th align="center" valign="middle">Over all (N=602)</th>
<th align="center" valign="middle">IVIG-responsive (N=534)</th>
<th align="center" valign="middle">IVIG-resistant (N=68)</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Male sex</td>
<td valign="top" align="center">361 (60.00)</td>
<td valign="top" align="center">321 (60.11)</td>
<td valign="top" align="center">40 (58.82)</td>
<td valign="top" align="center">0.838</td>
</tr>
<tr>
<td valign="top" align="left">Age (mo)</td>
<td valign="top" align="center">25 (13,45)</td>
<td valign="top" align="center">25 (13,45)</td>
<td valign="top" align="center">29 (14,40)</td>
<td valign="top" align="center">0.898</td>
</tr>
<tr>
<td valign="top" align="left">WBC (&#x000D7;10<sup>9</sup>/L)</td>
<td valign="top" align="center">14.08 (10.95&#x02013;17.61)</td>
<td valign="top" align="center">14.20 (11.14&#x02013;17.61)</td>
<td valign="top" align="center">13.35 (10.10&#x02013;17.45)</td>
<td valign="top" align="center">0.281</td>
</tr>
<tr>
<td valign="top" align="left">Neutrophil (&#x000D7;10<sup>9</sup>/L)</td>
<td valign="top" align="center">9.09 (6.29&#x02013;12.76)</td>
<td valign="top" align="center">9.15 (6.29&#x02013;12.60)</td>
<td valign="top" align="center">8.83 (6.24&#x02013;13.34)</td>
<td valign="top" align="center">0.902</td>
</tr>
<tr>
<td valign="top" align="left">Lymphocyte (&#x000D7;10<sup>9</sup>/L)</td>
<td valign="top" align="center">3.16 (1.96&#x02013;4.46)</td>
<td valign="top" align="center">3.21(2.06&#x02013;4.57)</td>
<td valign="top" align="center">2.27 (1.52&#x02013;3.97)</td>
<td valign="top" align="center"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">Eosinophil (&#x000D7;10<sup>9</sup>/L)</td>
<td valign="top" align="center">0.26(0.10&#x02013;0.52)</td>
<td valign="top" align="center">0.27(0.10&#x02013;0.54)</td>
<td valign="top" align="center">0.14 (0.04&#x02013;0.34)</td>
<td valign="top" align="center"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">Monocyte (&#x000D7;10<sup>9</sup>/L)</td>
<td valign="top" align="center">0.90 (0.59&#x02013;1.28)</td>
<td valign="top" align="center">0.92 (0.61&#x02013;1.26)</td>
<td valign="top" align="center">0.76 (0.44&#x02013;1.30)</td>
<td valign="top" align="center">0.057</td>
</tr>
<tr>
<td valign="top" align="left">Basophil (&#x000D7;10<sup>9</sup>/L)</td>
<td valign="top" align="center">0.03 (0.02&#x02013;0.05)</td>
<td valign="top" align="center">0.03 (0.02&#x02013;0.05)</td>
<td valign="top" align="center">0.04 (0.02&#x02013;0.06)</td>
<td valign="top" align="center">0.997</td>
</tr>
<tr>
<td valign="top" align="left">Platelet (&#x000D7;10<sup>9</sup>/L)</td>
<td valign="top" align="center">340 (267&#x02013;435)</td>
<td valign="top" align="center">344 (273&#x02013;433)</td>
<td valign="top" align="center">290 (209&#x02013;443)</td>
<td valign="top" align="center"><bold>0.011</bold></td>
</tr>
<tr>
<td valign="top" align="left">Hemoglobin (g/L)</td>
<td valign="top" align="center">106 (97&#x02013;114)</td>
<td valign="top" align="center">107 (98&#x02013;114)</td>
<td valign="top" align="center">98 (89&#x02013;106)</td>
<td valign="top" align="center"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">Na<sup>+</sup> (mmol/L)</td>
<td valign="top" align="center">136.9 (135.1&#x02013;138.2)</td>
<td valign="top" align="center">136.9 (135.3&#x02013;138.3)</td>
<td valign="top" align="center">136.0 (133.9&#x02013;136.9)</td>
<td valign="top" align="center"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">ESR (mm/hr)</td>
<td valign="top" align="center">59.5 (44&#x02013;80)</td>
<td valign="top" align="center">59.5 (46&#x02013;80)</td>
<td valign="top" align="center">59.5 (37&#x02013;80)</td>
<td valign="top" align="center">0.542</td>
</tr>
<tr>
<td valign="top" align="left">CRP (mg/L)</td>
<td valign="top" align="center">78.5 (48.6&#x02013;134.5)</td>
<td valign="top" align="center">76.5 (45.4&#x02013;127.0)</td>
<td valign="top" align="center">111.6 (60.5&#x02013;162.8)</td>
<td valign="top" align="center"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">GGT (U/L)</td>
<td valign="top" align="center">29 (14&#x02013;87)</td>
<td valign="top" align="center">28 (13&#x02013;84)</td>
<td valign="top" align="center">49 (19&#x02013;95)</td>
<td valign="top" align="center">0.09</td>
</tr>
<tr>
<td valign="top" align="left">LDH (U/L)</td>
<td valign="top" align="center">320 (278&#x02013;365)</td>
<td valign="top" align="center">321 (278&#x02013;364)</td>
<td valign="top" align="center">316 (280&#x02013;371)</td>
<td valign="top" align="center">0.851</td>
</tr>
<tr>
<td valign="top" align="left">DBIL (&#x003BC;mol/L)</td>
<td valign="top" align="center">2.9 (1.9&#x02013;5.0)</td>
<td valign="top" align="center">2.8 (1.9&#x02013;4.4)</td>
<td valign="top" align="center">3.9 (2.2&#x02013;7.0)</td>
<td valign="top" align="center"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">TBIL (&#x003BC;mol/L)</td>
<td valign="top" align="center">6.3 (4.2&#x02013;9.3)</td>
<td valign="top" align="center">6.1 (4.1&#x02013;8.9)</td>
<td valign="top" align="center">7.2 (4.8&#x02013;12.0)</td>
<td valign="top" align="center"><bold>0.014</bold></td>
</tr>
<tr>
<td valign="top" align="left">Globulin (g/L)</td>
<td valign="top" align="center">24.10 (21.33&#x02013;27.56)</td>
<td valign="top" align="center">24.06 (21.26&#x02013;27.03)</td>
<td valign="top" align="center">26.47 (22.08&#x02013;37.23)</td>
<td valign="top" align="center"><bold>0.002</bold></td>
</tr>
<tr>
<td valign="top" align="left">Albumin (g/L)</td>
<td valign="top" align="center">37.65 (33.89&#x02013;41.03)</td>
<td valign="top" align="center">37.65 (34.64&#x02013;41.07)</td>
<td valign="top" align="center">33.33 (29.28&#x02013;39.08)</td>
<td valign="top" align="center"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td valign="top" align="left">AST (U/L)</td>
<td valign="top" align="center">33 (26&#x02013;49)</td>
<td valign="top" align="center">33 (25&#x02013;48)</td>
<td valign="top" align="center">40 (28&#x02013;63)</td>
<td valign="top" align="center"><bold>0.039</bold></td>
</tr>
<tr>
<td valign="top" align="left">ALT (U/L)</td>
<td valign="top" align="center">27 (15&#x02013;72)</td>
<td valign="top" align="center">27 (15&#x02013;75)</td>
<td valign="top" align="center">32 (18&#x02013;68)</td>
<td valign="top" align="center">0.245</td>
</tr>
<tr>
<td valign="top" align="left">Incomplete KD</td>
<td valign="top" align="center">220 (36.55)</td>
<td valign="top" align="center">189 (35.39)</td>
<td valign="top" align="center">31 (45.59)</td>
<td valign="top" align="center">0.1</td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>Values are presented as number (%) or median (interquartile range).</p>
<p>IVIG, intravenous immunoglobulin; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; GGT, gamma-glutamyl transpeptidase; LDH, lactate dehydrogenase; DBIL, direct bilirubin; TBIL, total bilirubin; AST, aspartate transaminase; ALT, alanine aminotransferase; KD, Kawasaki disease.</p>
<p>Boldface indicates a statistically significant difference with <italic>P</italic>&lt;0.05.</p></fn>
</table-wrap-foot>
</table-wrap>

<table-wrap id="t2-cep-2024-00549" position="float">
<label>Table 2.</label>
<caption><p>Factors associated with IVIG-resistance</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle" rowspan="2">Variable</th>
<th align="center" valign="middle" colspan="3">Univariate analysis<hr/></th>
<th align="center" valign="middle" colspan="3">Multivariate analysis<hr/></th>
</tr><tr>
<th align="center" valign="middle">OR</th>
<th align="center" valign="middle">95% CI</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
<th align="center" valign="middle">OR</th>
<th align="center" valign="middle">95% CI</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Male sex</td>
<td valign="top" align="center">0.948</td>
<td valign="top" align="center">0.567&#x02013;1.583</td>
<td valign="top" align="center">0.838</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">Age</td>
<td valign="top" align="center">1.000</td>
<td valign="top" align="center">0.991&#x02013;1.01</td>
<td valign="top" align="center">0.931</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">Incomplete KD</td>
<td valign="top" align="center">1.529</td>
<td valign="top" align="center">0.919&#x02013;2.545</td>
<td valign="top" align="center">0.102</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">WBC</td>
<td valign="top" align="center">0.985</td>
<td valign="top" align="center">0.942&#x02013;1.031</td>
<td valign="top" align="center">0.522</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">Neutrophil</td>
<td valign="top" align="center">1.014</td>
<td valign="top" align="center">0.967&#x02013;1.064</td>
<td valign="top" align="center">0.554</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">Lymphocyte</td>
<td valign="top" align="center">0.78</td>
<td valign="top" align="center">0.664&#x02013;0.917</td>
<td valign="top" align="center"><bold>0.003</bold></td>
<td valign="top" align="center">0.843</td>
<td valign="top" align="center">0.696&#x02013;1.005</td>
<td valign="top" align="center">0.068</td>
</tr>
<tr>
<td valign="top" align="left">Monocyte</td>
<td valign="top" align="center">0.991</td>
<td valign="top" align="center">0.654&#x02013;1.501</td>
<td valign="top" align="center">0.965</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">Eosinophil</td>
<td valign="top" align="center">0.364</td>
<td valign="top" align="center">0.152&#x02013;0.874</td>
<td valign="top" align="center"><bold>0.024</bold></td>
<td valign="top" align="center">0.426</td>
<td valign="top" align="center">0.145&#x02013;1.098</td>
<td valign="top" align="center">0.098</td>
</tr>
<tr>
<td valign="top" align="left">Basophil</td>
<td valign="top" align="center">0.936</td>
<td valign="top" align="center">0.002&#x02013;545.768</td>
<td valign="top" align="center">0.984</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">GGT</td>
<td valign="top" align="center">1.001</td>
<td valign="top" align="center">0.998&#x02013;1.003</td>
<td valign="top" align="center">0.706</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">Na<sup>+</sup></td>
<td valign="top" align="center">0.85</td>
<td valign="top" align="center">0.78&#x02013;0.926</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
<td valign="top" align="center">0.871</td>
<td valign="top" align="center">0.792&#x02013;0.956</td>
<td valign="top" align="center"><bold>0.004</bold></td>
</tr>
<tr>
<td valign="top" align="left">Hemoglobin</td>
<td valign="top" align="center">0.956</td>
<td valign="top" align="center">0.937&#x02013;0.975</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
<td valign="top" align="center">0.947</td>
<td valign="top" align="center">0.925&#x02013;0.969</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
</tr>
<tr>
<td valign="top" align="left">Platelet</td>
<td valign="top" align="center">0.999</td>
<td valign="top" align="center">0.997&#x02013;1.001</td>
<td valign="top" align="center">0.291</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">ESR</td>
<td valign="top" align="center">0.997</td>
<td valign="top" align="center">0.988&#x02013;1.007</td>
<td valign="top" align="center">0.585</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">AST</td>
<td valign="top" align="center">1.000</td>
<td valign="top" align="center">0.997&#x02013;1.003</td>
<td valign="top" align="center">0.93</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">Albumin</td>
<td valign="top" align="center">0.892</td>
<td valign="top" align="center">0.853&#x02013;0.933</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
<td valign="top" align="center">0.972</td>
<td valign="top" align="center">0.922&#x02013;1.024</td>
<td valign="top" align="center">0.287</td>
</tr>
<tr>
<td valign="top" align="left">Globulin</td>
<td valign="top" align="center">1.074</td>
<td valign="top" align="center">1.041&#x02013;1.107</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
<td valign="top" align="center">1.081</td>
<td valign="top" align="center">1.047&#x02013;1.117</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
</tr>
<tr>
<td valign="top" align="left">TBIL</td>
<td valign="top" align="center">1.009</td>
<td valign="top" align="center">0.997&#x02013;1.021</td>
<td valign="top" align="center">0.159</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">DBIL</td>
<td valign="top" align="center">1.026</td>
<td valign="top" align="center">1.007&#x02013;1.045</td>
<td valign="top" align="center"><bold>0.008</bold></td>
<td valign="top" align="center">1.016</td>
<td valign="top" align="center">0.994&#x02013;1.038</td>
<td valign="top" align="center"><bold>0.157</bold></td>
</tr>
<tr>
<td valign="top" align="left">LDH</td>
<td valign="top" align="center">1.001</td>
<td valign="top" align="center">0.998&#x02013;1.004</td>
<td valign="top" align="center">0.475</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">CRP</td>
<td valign="top" align="center">1.008</td>
<td valign="top" align="center">1.004&#x02013;1.011</td>
<td valign="top" align="center"><bold>&lt;0.01</bold></td>
<td valign="top" align="center">1.005</td>
<td valign="top" align="center">1.001&#x02013;1.009</td>
<td valign="top" align="center"><bold>0.025</bold></td>
</tr>
<tr>
<td valign="top" align="left">ALT</td>
<td valign="top" align="center">0.999</td>
<td valign="top" align="center">0.996&#x02013;1.002</td>
<td valign="top" align="center">0.577</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>IVIG, intravenous immunoglobulin; OR, odds ratio; CI, confidence interval; KD, Kawasaki disease; WBC, white blood cell; GGT, gamma-glutamyl transpeptidase; ESR, erythrocyte sedimentation rate; AST, aspartate transaminase; TBIL, total bilirubin; DBIL, direct bilirubin; LDH, lactate dehydrogenase; CRP, C-reactive protein; ALT, alanine aminotransferase.</p>
<p>Boldface indicates a statistically significant difference with <italic>P</italic>&lt;0.05.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</back></article>